Targeting secretory leukocyte protease inhibitor (SLPI) inhibits colorectal cancer cell growth, migration and invasion via downregulation of AKT

PeerJ

article

Zhijiang Wei¹  Guiying Liu¹  Rufu Jia²  Wei Zhang¹  Li Li²  Yuanyuan Zhang¹  Zhijing Wang²  Xiyong Bai¹ 

[1] The First Department of Surgical Oncology, Cangzhou Central Hospital;The Brain Science Unit, CangZhou Central Hospital

关键词: Secretory leukocyte protease inhibitor;    Colorectal cancer;    AKT;   

DOI  :  10.7717/peerj.9400

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

The secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor which plays important role in bacterial infection, inflammation, wound healing and epithelial proliferation. Dysregulation of SLPI has been reported in a variety of human cancers including glioblastoma, lung, breast, ovarian and colorectal carcinomas and is associated with tumor aggressiveness and metastatic potential. However, the pathogenic role of SLPI in colorectal cancer is still unclear. Here we showed that SLPI mRNA level was significantly upregulated in colorectal cancer tissues compared to adjacent normal controls. Targeting SLPI by siRNA inhibited proliferation, migration and invasion of colorectal cancer cells lines HT29 and HT116 in vitro. Mechanistically, blockage of cancer cell growth and metastasis after SLPI knockdown was associated with down-regulation of AKT signaling. In conclusion, SLPI regulated colorectal cell growth and metastasis via AKT signaling. SLPI may be a novel biomarker and therapeutic target for colorectal cancer. Targeting AKT signaling may be effective for colorectal cancer treatment.

【 授权许可】

CC BY